What the ASA ruled on weight-loss drug adverts
The Advertising Standards Authority issued rulings against five pharmacies on 7 October 2026 over the promotion of weight-loss medicines to the public in the UK, according to reporting by the Daily Mail. The decisions cover adverts for oral treatments and marketing that allowed consumers to identify prescription-only medicines even when no product was named.
The pharmacies named in the report are Simple Online Pharmacy, Pharmacy Online, MedExpress, Juniper and the Care Pharmacy. Alongside the decisions, the watchdog issued guidance intended to make the boundaries for advertising weight-loss treatments clearer.
The action applies an existing prohibition, rather than introducing a new ban on these medicines. UK law bars direct-to-public advertising of prescription-only drugs and the promotion of medicines that have not received regulatory authorisation.
Simple Online Pharmacy’s advert, seen on 1 June, invited people to register their interest in an unnamed forthcoming oral weight-loss treatment. The Daily Mail reports that a tablet version of Wegovy became the first oral GLP-1 medicine authorised for weight management in the UK on 11 June, ten days after the advert appeared.
Pharmacy Online’s case concerned website pop-ups and social media material promoting an unnamed weight-loss pill after it had been authorised as a prescription-only medicine. The distinction is important: obtaining a licence permits a medicine’s use under its authorised conditions, but does not permit consumer advertising when it requires a prescription.
The rulings against MedExpress, Juniper and the Care Pharmacy addressed the impression created by adverts as a whole. According to the report, the ASA concluded that consumers could recognise prescription-only weight-loss medicines from the marketing without seeing their names.
The guidance also warns against using pictures of injection pens or language about suppressing appetite and cravings where these would allow an audience to infer that a prescription medicine was being promoted.
How UK advertising rules apply to GLP-1 medicines
Wegovy and Mounjaro are prescription-only medicines used for weight management. Wegovy contains semaglutide, which acts on GLP-1 receptors involved in appetite regulation. Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. Both can reduce hunger and food intake, but treatment requires assessment of suitability and possible risks.
The advertising restriction separates a clinical prescribing decision from a commercial invitation to seek a particular medicine. It does not prevent an eligible patient receiving treatment, nor does it make the medicines themselves unlawful to supply on prescription.
For pharmacies, the distinction between promoting a healthcare service and promoting the medicine supplied through it is central. Describing a consultation service is not necessarily equivalent to advertising a prescription product; the wording, imagery and overall presentation can nevertheless cross that boundary.
The latest decisions follow nine ASA rulings in July 2025. The Daily Mail reports that those decisions allowed limited references to weight-loss injections on pharmacy websites away from homepages, while restricting their use in advertising. Marketing was expected to concern a broader service involving consultation and prescribing, rather than injections offered as a standalone treatment.
NHS access to weight-management medicines is subject to eligibility criteria and service arrangements; regulatory authorisation alone does not guarantee NHS provision. The Daily Mail puts the number of Britons using weight-loss drugs at more than 2.5 million, with most paying privately because NHS access remains limited.
What the ASA and MHRA said about the adverts
Catherine Drewett, the ASA’s investigations manager, said the arrival of oral weight-loss medicines had brought additional regulatory challenges. She said the decisions established that prescription tablets were subject to the same public-advertising restriction as prescription injections.
“These are powerful medicines,” Drewett said, warning against advertising that could encourage people to seek treatment in potentially unsafe ways.
The Medicines and Healthcare products Regulatory Agency welcomed the ASA’s action. Julian Breach, its interim executive director of healthcare, said: “Stimulating consumer demand for a new prescription medicine is not permitted.”
Breach said organisations promoting medicines were expected to comply fully with advertising requirements and that the MHRA could use its regulatory powers where breaches occurred. The report identifies fines and court proceedings among possible enforcement measures. Referrals to the General Pharmaceutical Council can also lead to action involving a pharmacy, its owner or its superintendent pharmacist.
Separately, the ASA told the Daily Mail that it had received several complaints about an Eli Lilly campaign broadcast on Channel 4 in the advertising break following The Great British Bake Off the previous week. Lilly makes Mounjaro.
That campaign presented obesity as a disease without naming a medicine. The Daily Mail reports criticism that it could nonetheless encourage interest in prescription treatment. Those complaints are distinct from the five pharmacy rulings: the report does not establish a regulatory finding against Lilly’s campaign.
What happens next for pharmacies and Lilly’s campaign
Pharmacies will need to assess more than whether a product name appears in their advertising. The latest decisions make the combination of images, treatment claims and surrounding material relevant to whether an advert promotes a prescription-only medicine.
The ASA said another regulator had taken over the Lilly complaints because they concerned a pharmaceutical company campaign rather than a specific medicine. The Daily Mail’s account does not identify that regulator or give a timetable for a decision.
It also remains unclear whether the advertising action will materially reduce unlawful promotion or sales. The reported rulings concern marketing compliance; they do not establish that the pharmacies supplied medicines illegally or that any patient was harmed.
